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Abstract
Peroxisome proliferator-activated receptors (PPARs) are a nuclear receptor family of ligand-inducible transcription factors,
which have three different isoforms: PPARa, d and c. It has been demonstrated that PPARa and c agonists have
renoprotective effects in proteinuric kidney diseases; however, the role of PPARd agonists in kidney diseases remains
unclear. Thus, we examined the renoprotective effect of GW501516, a PPARd agonist, in a protein-overload mouse
nephropathy model and identified its molecular mechanism. Mice fed with a control diet or GW501516-containing diet were
intraperitoneally injected with free fatty acid (FFA)-bound albumin or PBS(2). In the control group, protein overload caused
tubular damages, macrophage infiltration and increased mRNA expression of MCP-1 and TNFa. These effects were
prevented by GW501516 treatment. In proteinuric kidney diseases, excess exposure of proximal tubular cells to albumin,
FFA bound to albumin or cytokines such as TNFa is detrimental. In vitro studies using cultured proximal tubular cells
showed that GW501516 attenuated both TNFa- and FFA (palmitate)-induced, but not albumin-induced, MCP-1 expression
via direct inhibition of the TGF-b activated kinase 1 (TAK1)-NFkB pathway, a common downstream signaling pathway to
TNFa receptor and toll-like receptor-4. In conclusion, we demonstrate that GW501516 has an anti-inflammatory effect in
renal tubular cells and may serve as a therapeutic candidate to attenuate tubulointerstitial lesions in proteinuric kidney
diseases.
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Introduction
Proteinuria is not only a clinical indicator of chronic kidney
disease (CKD), but also a detrimental factor in progressive CKD
[1,2,3]. In proteinuric kidney diseases, excessive albumin and
several macromolecules bound to albumin, including free fatty
acid (FFA), are filtered from glomeruli and reabsorbed into
proximal tubular cells. This causes an inflammatory vicious cycle
via secretion of pro-inflammatory cytokines, such as monocyte
chemoattractant protein-1 (MCP-1), and subsequent infiltration of
inflammatory cells, which secrete tumor necrotic factor-a (TNFa)
[1,2,3,4,5]. Continuous inflammation triggers tubular cell damage,
fibrosis and eventually progression to the final stage of kidney
disease [5,6]. Thus, suppression of inflammation caused by all
these factors should serve as an important means to protect
proximal tubular cells and maintain renal function in proteinuric
kidney diseases.
Peroxisome proliferator-activated receptors (PPARs) are a
nuclear receptor family of ligand-inducible transcription factors,
composed of three different isoforms: PPARa, PPARd and PPARc
[7,8]. Acting as transcription factors, PPARs regulate various
metabolic processes involving lipid metabolism, glucose homeo-
stasis, cell differentiation and inflammation [7,8,9,10,11]. Recent
reports demonstrated that PPARa and -c agonists show
renoprotective effects in a PPAR-dependent and independent
manner [12,13,14,15,16,17]; however, the physiological role and
therapeutic potential of PPARd in the kidney remain unclear.
Several reports have shown that PPARd agonists are potentially
anti-inflammatory agents in some cell types and animal models
[18,19,20,21]. In summary, PPARd agonists may show anti-
inflammatory effects in renal proximal tubular cells and could be
promising new therapeutic candidates for proteinuric kidney
diseases.
To certify this hypothesis, we investigated whether GW501516,
a highly selective PPARd agonist [22], could attenuate tubuloin-
terstitial lesions in a protein-overload mouse model (an established
mouse model for studying interstitial lesions in proteinuric kidney
diseases [4,23]), and whether it could inhibit albumin-, saturated
FFA (palmitate)- and TNFa-induced inflammation in cultured
mouse proximal tubular cells. Our results showed that GW501516
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25271exerted an anti-inflammatory effect in proximal tubular cells in
both in vivo and in vitro studies, and it may be a promising new
candidate for slowing down the progression of proteinuric kidney
diseases.
Results
GW501516 attenuates interstitial inflammation and
proximal tubular cell damage in a protein-overload
mouse nephropathy model
To determine whether PPARd agonists exert anti-inflammatory
effects in vivo, we examined the effect of GW501516 on a protein-
overload mouse model. First, we confirmed that bovine serum
albumin (BSA) injection in mice increased urinary protein
excretion, and that treatment with GW501516 did not affect
basal and BSA-induced urinary protein excretion [(PBS(2) group:
3.2660.66, PBS(2) + GW501516 group: 3.2160.70, BSA group:
6.3661.26, BSA + GW501516 group: 6.6061.93 mg/day; data
are shown as means 6 SEM]. In mice fed with the control diet,
intraperitoneal protein overload induced significant and severe
tubular injury, characterized by diffused tubular cell vacuolation,
tubular cell flattening, tubular lumen dilation and cast formation
(Figure 1A and B). In the mice fed with the GW501516-containing
diet, these tubulointerstitial damages were significantly attenuated
(Figure 1A and B). The PBS(2) injection resulted in no apparent
changes in proximal tubular cells of either control or GW501516-
treated groups (Figure 1A and B).
Protein overload induced the prominent infiltration of F4/80-
positive macrophages into the renal interstitial area, which was
markedly attenuated by GW501516 treatment (Figure 2A).
Infiltration of F4/80-positive macrophages into glomeruli was
not observed in the kidney of any group of mice (Figure 2A). The
changes in F4/80 expression were confirmed by mRNA levels,
determined by real-time PCR (Figure 2B). Furthermore, protein
overload significantly increased mRNA expression levels of
inflammatory cytokines such as MCP-1, TNFa and IL-6. These
increases were significantly attenuated by GW501516 treatment
(Figure 2C, D and E). Protein overload and GW501516 treatment
did not affect PPARd expression levels in mice (data not shown).
These results suggest that GW501516 shows an anti-inflammatory
effect and protection of proximal tubular cells in the proteinuric
kidney disease mouse model.
GW501516 exerts anti-inflammatory effects in mouse
cultured proximal tubular (mProx) cells
Because proximal tubular cells are the direct victims of overflowed
protein [1,2,3], we examined the anti-inflammatory effect of
GW501516 on cultured mouse proximal tubular cells, treated with
pro-inflammatory molecules associated with proteinuria-induced
inflammation, such as FFA-free albumin [24,25], albumin-bound
saturated FFA (palmitate) [26] and TNFa. GW501516 failed to
inhibit FFA-free albumin-induced MCP-1 expression (Figure 3A).
However, GW501516 inhibited palmitate- and TNFa-induced
increases in MCP-1 mRNA expression in a dose-dependent manner
(Figure3B and C).Thesestimuliand treatment did not affect PPARd
expression levels (data not shown). These results suggest that the
GW501516-mediated suppression of MCP-1 expression is specific to
palmitate and TNFa in cultured mProx cells.
Figure 1. GW501516 attenuates renal proximal tubular cell damage in a protein-overload mouse renal injury model. (A)
Representative HE staining of kidney sections from four groups [PBS(2), PBS(2) + GW501516, Protein-overload and Protein-overload + GW501516]. In
the kidney of the protein-overload group, diffused tubular cell vacuolation (black triangles), tubular cell flattening (black arrows), tubular lumen
dilation (asterisks) and cast formation (white arrows) were observed (magnification 6100 and 6400). (B) Tubulointerstitial damage scores of kidney
sections from four groups. Data are shown as means 6 SEM of each individual group.
doi:10.1371/journal.pone.0025271.g001
PPARd Agonist in Proteinuric Kidney Disease
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25271PPARd is not required for GW501516-mediated anti-
inflammatory effects in cultured proximal tubular
(mProx) cells
The molecular mechanism of PPAR agonist-mediated anti-
inflammatory effects is cell-dependent [11,27]. Also, some PPAR
agonists have been shown to have an anti-inflammatory effect via
direct inhibition of an intracellular signaling pathway, but not via
ligand-activation of PPARs and subsequent upregulation of their
target genes [11,27]. Thus, we investigated whether PPARd itself
is required for the anti-inflammatory effect of GW501516 in
cultured mProx cells, using siRNA-mediated PPARd knockdown
and retrovirus-mediated PPARd overexpression. We confirmed
the decreased PPARd protein expression in siRNA-mediated
PPARd-knockdown mProx cells (Figure 4A). Furthermore, the
mRNA level of PPARd target genes was decreased in these cells
(Figure 4B). GW501516 significantly attenuated both palmitate-
and TNFa-induced MCP-1 expression levels in mProx cells
transfected with control siRNA (Figure 4C and D). This response
was not affected by siRNA-mediated PPARd knockdown
(Figure 4C and D). Moreover, we generated retrovirus-mediated
PPARd-overexpressing mProx cells and confirmed the functional
overexpression of PPARd (Figure 5A and B). The GW501516
inhibitory effect on both palmitate- and TNFa-induced MCP-1
expression was not enhanced in retrovirus-mediated PPARd-
overexpressing mProx cells (Figure 5C and D). Thus, neither
knockdown nor overexpression of PPARd changed the anti-
inflammatory effect of GW501516. These results suggest that
PPARd itself is not essential for the anti-inflammatory effect of
GW501516.
GW501516 exerts its anti-inflammatory effect by
inhibition of the TAK1-NFkB pathway
We continued to elucidate the identity of the signaling
molecules involved in the anti-inflammatory effect of
GW501516, specifically focusing on signaling molecules associated
with the NFkB pathway, which is a main inflammation regulatory
pathway. In cultured mProx cells incubated with palmitate,
phosphorylation of IkB and subsequent nuclear translocation of
Figure 2. GW501516 suppresses interstitial inflammation in a protein-overload mouse renal injury model. (A) Representative
photomicrographs of F4/80 immunostaining of the kidney from four groups [PBS(2), PBS(2) + GW501516, Protein-overload and Protein-overload +
GW501516] (magnification, upper: 6100, lower: 6400). Renal mRNA expression of F4/80 (B), MCP-1 (C), TNFa (D) and IL-6 (E) in kidney samples from
the four groups. Data are shown as means 6 SEM. Results are expressed as the fold change relative to the mean value of the mRNA expression level
of the PBS(2) group. MCP-1: monocyte chemoattractant protein-1; TNFa: tumor necrotic factor a.
doi:10.1371/journal.pone.0025271.g002
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expression of MCP-1 determined by real-time PCR in cultured mProx cells stimulated by 30% BSA (A), 150 mM palmitate (B) or 10 nM of TNFa (C) for
12 hours, with or without a 3-hour pretreatment of different concentrations of GW501516 (0, 2.5, 5 mM of GW501516 dissolved in 0.05% DMSO).
Results are expressed as fold change relative to control mRNA levels. Data are shown as means 6 SEM of at least four independent experiments.
MCP-1: monocyte chemoattractant protein-1; BSA: bovine serum albumin; TNFa: tumor necrotic factor a.
doi:10.1371/journal.pone.0025271.g003
Figure 4. Knockdown of PPARd gene expression does not
affect GW501516-mediated inhibition of MCP-1 expression in
mouse proximal tubular (mProx) cells treated with palmitate or
TNFa. (A) Representative immunoblot showing protein expression of
PPARd in siRNA-mediated PPARd-knockdown and control cells. (B)
mRNA expression of PPARd-target genes (PDK4 and ADRP) in PPARd-
knockdown and control cells treated with or without GW501516.
Results are expressed as fold change relative to the mRNA from the
control group. PDK4: Pyruvate dehydrogenase kinase 4; ADRP:
Adipocyte differentiation-related protein. The effect of PPARd knock-
down on GW501516-mediated inhibition of palmitate- (C) and TNFa-
(D) induced MCP-1 expression. Results are expressed as fold change
relative to the mRNA from the control group. Data are shown as means
6 SEM of three independent experiments. MCP-1: monocyte chemoat-
tractant protein-1; TNFa: tumor necrotic factor a.
doi:10.1371/journal.pone.0025271.g004
Figure 5. Overexpression of PPARd does not affect GW501516-
mediated attenuation of MCP-1 expression in mouse proximal
tubular (mProx) cells treated with palmitate or TNFa. (A)
Representative immunoblot showing protein expression of PPARd in
retrovirus-mediated PPARd-overexpressing cells and control cells. (B)
mRNA expression of PPARd-target genes (PDK4 and ADRP) in PPARd-
overexpressing and control cells treated with or without GW501516.
Results are expressed as fold change relative to the mRNA from the
control group. PDK4: Pyruvate dehydrogenase kinase 4; ADRP:
Adipocyte differentiation-related protein. The effect of PPARd overex-
pression on GW501516-mediated inhibition of palmitate- (C) and TNFa-
(D) induced MCP-1 expression. Results are expressed as fold change
relative to the mRNA from the control group. Data are shown as means
6 SEM of four independent experiments. MCP-1: monocyte chemoat-
tractant protein-1; TNFa: tumor necrotic factor a.
doi:10.1371/journal.pone.0025271.g005
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stimulation (Figure 6A). Palmitate-induced phosphorylation of IkB
and nuclear translocation of p65 were attenuated by pretreatment
with GW501516 (Figure 6B). Furthermore, we found that
GW501516 inhibited palmitate-induced DNA binding of p65 to
the MCP-1 promoter, as determined by chromatin immunopre-
cipitation (ChIP) analysis (Figure 6C). Next, we checked the
profiles of upstream and regulatory molecules associated with
receptor-mediated NFkB activation, such as mitogen activated
protein kinases (MAPKs; ERK, p38 and JNK) [28,29] and TGF-b
activated kinase 1 (TAK1) [30,31]. The phosphorylation levels of
the MAPKs and TAK1 were increased after 1 hour of palmitate
stimulation (Figure 6D). GW501516 inhibited the palmitate-
induced phosphorylation of TAK1 (Figure 6E and F), but not of
the MAPKs (Figure 6E).
Furthermore, we observed similar results with cultured mProx
cells incubated with TNFa. TNFa increased IkB phosphorylation
and subsequent nuclear translocation of p65 after 5 minutes of
stimulation (Figure 7A and 7B). These changes and DNA binding
of p65 to the MCP-1 promoter were significantly attenuated by
pretreatment with GW501516 (Figure 7C and D, respectively).
Finally, TAK1 phosphorylation was increased after 5 minutes of
TNFa stimulation (Figure 7E and F), which was suppressed by
pretreatment with GW501516 (Figure 7E and F).
GW501516 inhibited palmitate- and TNFa-induced phosphor-
ylation of TAK1 and IkB, and subsequent nuclear translocation of
p65 even in mProx cells transfected with siRNA against PPARd
(Figure 8A and B), suggesting that GW501516 inhibited the
TAK1-IkB pathway directly.
To investigate whether PPARd agonist-mediated inhibition of
TAK1 activation was specific to GW501516, we examined the
anti-inflammatory effect and mechanism of another PPARd
agonist, GW0742, in mProx cells. Similarly to GW501516,
GW0742 inhibited both palmitate- and TNFa-induced MCP-1
expression (Figure 9A and B) and suppressed TAK1 phosphory-
lation (Figure 9C, D, E and F). These results suggest that PPARd
agonist-mediated inhibition of TAK1 activation is not specific to
GW501516.
Discussion
The present study shows that GW501516 attenuated tubuloin-
terstitial lesions in a protein-overload nephropathy mouse model
and that its renoprotective effect was achieved by its anti-
inflammatory action in the kidney. These results highlight the
possibility that GW501516 may be a novel therapeutic candidate
for the improvement of renal prognosis in patients with proteinuric
kidney diseases.
Growing evidence has demonstrated that PPARd agonists have
therapeutic potential against various disease models [18,19,20,21,
22,32,33,34]. Recent reports have shown that PPARd agonists
attenuated obesity-related diseases such as insulin resistance,
diabetes and cardiovascular diseases, and regulated inflammatory
cell function, which potentiated a systemic inflammatory response
[18,19,20,21,22,32,33,34]. Furthermore, Letavernier et al. showed
the renoprotective effect of a PPARd agonist in an ischemic
reperfusion-mediated kidney injury [35]. In addition to these
findings, we present evidence that PPARd agonists have yet more
therapeutic potential against proteinuric kidney diseases.
The protein-overload model is a well-established model for
studying the renal tubulointerstitial lesions caused by proteinuria
[4,23]. In this model, upregulation of MCP-1 was demonstrated
Figure 6. GW501516 inhibits palmitate-induced NFkB activation via inhibition of TAK1 in mouse proximal tubular (mProx) cells. (A)
Immunoblot analysis showing palmitate-induced phosphorylation of IkB in the total cell lysate and nuclear translocation of the p65 subunit in a time
course experiment. (B) Immunoblot analysis showing the effect of GW501516 on palmitate-induced phosphorylation of IkB and nuclear translocation
of p65. The pretreatment time with GW501516 was 3 hours and the stimulation time with palmitate was 3 hours for phosphorylation of IkB and
nuclear translocation of p65. The images are representative pictures from three independent experiments. (C) Effect of GW501516 on DNA binding of
p65 to the MCP-1 promoter determined by chromatin immunoprecipitation (ChIP) analysis in palmitate-treated mProx. (D) Immunoblot analysis
showing palmitate-induced phosphorylation of MAPKs (P-ERK1/2, P-p38, P-JNK) and TAK1 in a time course experiment. (E) Immunoblot analysis
showing the effect of GW501516 on phosphorylation of MAPKs and TAK1. Pre-incubation time with GW501516 was 3 hours, and stimulation time
with palmitate was 1 hour. Images are representative figures from three independent experiments. TAK1: TGF-b activated kinase 1. (F) Quantitative
results of the ratio of band density of P-TAK1 and T-TAK1.
doi:10.1371/journal.pone.0025271.g006
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[36], which verified that attenuation of inflammation through
inhibition of MCP-1 should serve as a therapeutic target in
proteinuric kidney diseases. In our study, we confirmed that
protein overload induced MCP-1 expression and subsequent renal
inflammation, and these inflammation-associated renal damages
were attenuated by treatment with GW501516. To our knowl-
edge, this is the first report showing that a pharmacological agent
can improve tubulointerstitial lesions in this model.
Our in vitro study has identified the detailed molecular
mechanism underlying the anti-inflammatory effect of
GW501516 in the kidney. In proteinuric kidney diseases, albumin,
FFAs bound to albumin and inflammatory cytokines coordinately
mediate interstitial inflammation. In this study, we confirmed that
all of these factors induced overexpression of MCP-1 in cultured
proximal tubular cells via NFkB activation. Interestingly,
GW501516 attenuated MCP-1 expression induced by palmitate
and TNFa, but not albumin. These results suggest that the anti-
inflammatory effect of GW501516 is not universal in NFkB-
associated inflammatory processes; hence we focused on the
upstream signaling to NFkB. NFkB activation is regulated by a
variety of molecular pathways such as MAPKs and TAK1
Figure 7. GW501516 inhibits TNFa-induced NFkB activation via inhibition of TAK1 in mouse proximal tubular (mProx) cells.
Immunoblot analysis showing TNFa-induced phosphorylation of IkB and TAK1 (A) and nuclear translocation of the p65 subunit (B) in a time course
experiment. (C) Immunoblot analysis showing the effect of GW501516 on TNFa-induced phosphorylation of IkB and nuclear translocation of p65. The
pretreatment time with GW501516 was 3 hours and the stimulation time with TNFa was 5 minutes for phosphorylation of IkB and 10 minutes for
nuclear translocation of p65. Images are representative results from three independent experiments. (D) Effect of GW501516 on DNA binding of p65
to the MCP-1 promoter determined by chromatin immunoprecipitation (ChIP) analysis in TNFa-treated mProx cells. (E) Immunoblot analysis showing
the effect of GW501516 on TAK1 phosphorylation. Pre-incubation time with GW501516 was 3 hours and stimulation time with TNFa was 5 minutes.
(F) Quantitative result of the ratio of band density of P-TAK1 and T-TAK1. Images are representative figures from three independent experiments.
TAK1: TGF-b activated kinase 1; TNFa: tumor necrotic factor a.
doi:10.1371/journal.pone.0025271.g007
Figure 8. Knockdown of PPARd gene expression does not affect the GW501516-mediated inhibitory effect on the TAK1-NFkB
pathway in mouse proximal tubular (mProx) cells treated with palmitate or TNFa. Immunoblot analysis showing the effect of GW501516
on palmitate- (A) and TNFa- (B) induced phosphorylation of IkB and TAK1 in total cell lysate and nuclear translocation of the p65 subunit in siRNA-
mediated PPARd-knockdown and control cells. Images are representative figures from three independent experiments. TAK1: TGF-b activated kinase
1; TNFa: tumor necrotic factor a.
doi:10.1371/journal.pone.0025271.g008
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induced MCP-1 expression was MAPK (ERK)-dependent [25].
Here we show that GW501516 could not attenuate albumin-
induced MCP-1 expression, suggesting that inhibition of ERK
activity is not the target of the anti-inflammatory effect of
GW501516. In contrast, GW501516 inhibited palmitate- and
TNFa-induced MCP-1 expression via the inhibition of TAK1
activation, without affecting MAPK activity. Furthermore,
albumin failed to induce phosphorylation of TAK1 (data not
shown). Thus, for the first time, we concluded that inhibition of
TAK1, but not MAPKs, is involved in the mechanism underlying
the anti-inflammatory effect of GW501516 (Figure 10). To our
knowledge, few reports have shown the interaction between PPAR
agonists and TAK1. Our current findings may enrich the
knowledge of anti-inflammatory mechanisms of PPAR agonists.
To date, the mechanism underlying the anti-inflammatory effect
of PPARd agonists has been focused on BCL6 protein. The release
of BCL6 from PPARd is known to contribute to any of the anti-
inflammatory actions of PPARd agonists in macrophages, both in
vitro [21,37] and in vivo [21]. In other tissues it is not so clear; the
inhibitory actions of PPARd on adhesion molecules expression in
endothelial cells have been reported to be both BCL6-dependent
[38] and BCL6-independent [39], suggesting that the BCL6
theory is cell-specific and ligand-specific. We showed that
suppression of PPARd gene expression had no effect on MCP-1
expression in mProx cells, indicating that BCL6 is not involved in
the anti-inflammatory mechanism of GW501516 in proximal
tubular cells.
Also in our study, we demonstrated that PPARd itself is not
essential for the anti-inflammatory effect of GW501516. The
knockdown or overexpression of PPARd could neither impede nor
enhance the anti-inflammatory action of GW501516. GW501516
has been shown to exert an anti-inflammatory effect in many cell
types [18,19,20,21], but whether or not this effect is mediated
through the PPARd receptor has not been clarified. Although we
demonstrated that two types of PPARd agonists, GW501516 and
GW0742, did not require PPARd itself for their anti-inflammatory
effects in cultured proximal tubular cells, it remains to be
confirmed whether all PPARd agonists function similarly, to
conclude whether this mechanism is specific for GW501516 and
GW0742 or global for PPARd agonists. Furthermore, to elucidate
whether GW501516 can improve renal inflammation in a PPARd-
independent manner in vivo, further examination of the effect of
GW501516 on the progression of tubulointerstitial lesions induced
by protein overload in PPARd knockout mice is required.
Figure 9. GW0742 inhibits palmitate- and TNFa-induced MCP-1
expression as well as TAK1 phosphorylation in mouse
proximal tubular (mProx) cells. mRNA expression of MCP-1
determined by real-time PCR in cultured mProx cells stimulated by
150 mM palmitate (A) or 10 nM TNFa (B) for 12 hours, with or without a
3-hour pretreatment with GW0742 (5 mM GW0742 dissolved in 0.05%
DMSO). Results are expressed as fold change relative to control mRNA
levels. (C) Immunoblot analysis showing palmitate-induced phosphor-
ylation of TAK1. (D) Quantitative result of the ratio of band density of P-
TAK1 and T-TAK1. (E) Immunoblot analysis showing TNFa-induced
phosphorylation of TAK1. (F) Quantitative result of the ratio of band
density of P-TAK1 and T-TAK1. MCP-1: monocyte chemoattractant
protein-1. TNFa: tumor necrotic factor a; TAK1: TGF-b activated kinase 1.
Data are shown as means 6 SEM of at least three independent
experiments.
doi:10.1371/journal.pone.0025271.g009
Figure 10. Proposed mechanism underlying the GW501516-
mediated anti-inflammatory effect in proximal tubular cells in
proteinuric kidney diseases. Both TNFa and palmitate induce the
phosphorylation of TAK1 in a receptor dependent manner. The
phosphorylation of TAK1 activates the NFkB pathway via degradation
of IkB. The p65 subunit of NFkB translocates into the nucleus,
upregulates the transcription of the pro-inflammatory gene, MCP-1,
and causes inflammation. GW501516 can inhibit the phosphorylation of
TAK1, but not of MAPKs (including ERK), and the activation of the NFkB-
associated inflammatory response in proximal tubular cells. TNFa:
tumor necrotic factor a; TNFR: TNFa receptor; TLR4: toll-like receptor 4;
IKK: IkB Kinase; FFA: free fatty acid; MCP-1: monocyte chemoattractant
protein-1.
doi:10.1371/journal.pone.0025271.g010
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e25271In conclusion, we demonstrated that GW501516, a PPARd
agonist, showed a renoprotective effect by exerting an anti-
inflammatory effect in proximal tubular cells, both in vivo and in
vitro. Thus, it may be a promising candidate for slowing down the
progression of chronic kidney diseases.
Materials and Methods
Antibodies and reagents
Antibodies were purchased from the following sources: TAK1
polyclonal antibody, phospho-TAK1 (T187), IkB-a, phospho-
IkBa, p38-MAPK, phospho-p38-MAPK (Thr180/Tyr182), p44/
42 MAPK, phospho-p44/42 MAPK, SAPK/JNK, phospho-
SAPK/JNK (T183/Y185), Histone H3 and NFkB p65 were from
Cell Signaling Technology (Beverly, MA, USA). Recombinant
TNFa, sodium palmitate, albumin from bovine serum and
GW0742 were purchased from Sigma (St. Louis, MO, USA).
Small interference RNA against PPARd was purchased from
Applied Biosystems Japan, Ltd. GW501516 was from Glaxo-
SmithKline (London, UK).
Animals.
Animal care and treatment were performed in accordance with
the guidelines of the Research Center for Animal Life Science of
Shiga University of Medical Science (approval ID: 2010-2-13).
Seven-week-old male C57BL/6 mice (CLEA Japan, Tokyo, Japan)
were housed at a constant room temperature, 12-h dark/12-h light
cycle, and freely fed a standard diet and tap water. Mice were
randomly allocated to different groups and received therapeutic
diet and treatment. The GW501516-containing rodent diet was
made by evenly adding GW501516 to the control diet to a final
concentration of 0.04% w/w. In the control diet, 10% of the total
calories were from fat (5.5% from soybean oil and 4.5% from
lard). All foods were purchased from Research Diets (New
Brunswick, NJ, USA).
Protein-overload mouse nephropathy model
Animal experiments were performed as described previously,
with minor modifications [4,23]. FFA-bound BSA was adminis-
tered by intraperitoneal injection to induce renal tubulointerstitial
damages. Mice were divided into the following four groups:
PBS(2), PBS(2) + GW501516, protein-overload and protein-
overload + GW501516 (n=3, 4, 6 and 6, respectively). Mice were
fed either a control diet or a GW501516-containing diet. Each
group was given its diet for 10 days before starting treatments.
Once a day for the following 4 days, the mice of each group were
given an intraperitoneal injection of either 10 mg/g body weight
FFA-bound BSA diluted in sterile PBS(2) or an equal volume of
sterile PBS(2) as a control. On the fifth day, mice were
anesthetized with intraperitoneal injection of pentobarbital
sodium, then blood was drawn from the right atrium with a
heparinized syringe and serum was separated for biochemical
assays. Kidneys were removed for mRNA assays, histological
examination and immunohistochemical staining, as previously
reported [40,41]. Urinary protein concentrations were measured
with the Bradford method.
Histological analyses
Fixed kidneys embedded in paraffin were sectioned to 3 mm
thickness [40,41]. Semiquantitative histological analysis of the
tubular damage was performed using HE-stained sections from
each mouse. Tubular damage scores, ranging from 0 to 4, were
assessed according to both the severity and range of proximal
tubular damages; an average was taken from the final score of 20
randomly selected, non-overlapping cortical areas under 6200
magnification [42]. Immunohistochemical staining was performed
with the F4/80-specific monoclonal anti-rat antibody (Serotec,
Oxford, UK), as previously described [40].
Cell culture
Immortalized murine proximal tubular cells (mProx) were
established as described previously [25]. First, we confirmed that
the dosage of GW501516 used in the following experiments was
not cytotoxic to the cells by using the AlamarBlue
TM Assay
(Alamar Bioscience, Sacramento, CA, USA; data not shown). Cells
were cultured in DMEM containing 10% FBS, 100 U/ml
penicillin and 100 mg/ml streptomycin at 37uC and 5% CO2
thermostat. Subconfluent cells were starved by incubation in 0.2%
FCS DMEM for 9 h, then preincubated with GW501516
[dissolved in 10% dimethyl sulfoxide (DMSO)], at a final
concentration of 2.5 and 5 mM, or 0.05% DMSO as control for
3 hours, followed by stimulation with 150 mM palmitate bound to
8.0% BSA for 12 h. We also performed the same experiment
under stimulation with 10 nM TNFa and 30% BSA.
Quantitative real-time PCR
Total RNAs were isolated from the kidney samples and cultured
cells, and cDNAs were synthesized as previously reported [41].
The iQSYBR Green Supermix (Bio-Rad Laboratories, Hercules,
CA, USA) was used for real-time PCR (ABI Prism TM 7500
Sequence Detection System; Perkin-Elmer Applied Biosystems,
Foster City, CA, USA). The mRNA expression levels were
quantified using the standard curve method [41]. Analytical data
were normalized to the mRNA expression level of GAPDH as an
internal control. Primer sequences are described in Table 1.
Immunoblotting
Total cell lysates for immunoblotting were collected as
previously described [43,44]. For detecting nuclear translocation
of p65, nuclear extracts were prepared as previously described
[43,44]. Equal amounts of protein samples were resolved by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
transferred to polyvinylidene fluoride membranes (Immobilon,
Bedford, MA, USA). The membranes were incubated with the
appropriate antibodies, washed and incubated with horseradish
peroxidase-coupled secondary antibodies (Amersham, Buckin-
ghamshire, UK). After washing, the blots were visualized by using
an enhanced chemiluminescence detection system (Perkin Elmer
Life Science, Boston, MA, USA).
Small interference RNA transfections against PPARd
Control siRNA and siRNA against PPARd were purchased from
Ambion (Austin, TX, USA). Transient transfections of siRNA
were performed using Lipofectamin 2000 (Invitrogen, Carlsbad,
CA, USA) [43,44]. To determine the effect of siRNA against
PPARd on palmitate- and TNFa-induced MCP-1 expression, all
experiments were performed 24 h post-siRNA transfection.
ChIP analysis
The ChIP experiment was performed using the ChIP-IT kit
from Active Motif (Carlsbad, CA, USA) according to the
manufacturer’s instructions [44]. The primer sequences are listed
in Table 1.
Retroviral infection
pBABE-PPARd vectors were obtained from Addgene. Retrovi-
ral infections were performed as previously described [43,44].
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pBABE-PPARd using Lipofectamin 2000 reagent. Forty-eight
hours post-transfection, the media containing retroviruses were
collected, centrifuged, and transferred into the cultured proximal
tubular cells, which were pre-treated with polybrene (1 mg/mL) for
30 min. Retrovirus-infected cells were selected by treatment with
puromycin (2.5 mg/mL) for several days. We confirmed overex-
pression of PPARd by immunoblotting and real-time PCR.
Statistical analysis
Results are expressed as mean 6 SEM. ANOVA with
subsequent Scheffe test was used to determine the significance of
differences in multiple comparisons. A p value ,0.05 was
considered statistically significant.
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